BioCentury
ARTICLE | Clinical News

2B3-201: Phase I data

September 29, 2014 7:00 AM UTC

A double-blind, crossover, Dutch Phase I trial in 18 healthy male volunteers showed that single ascending doses of up to 450 mg 2B3-201 were well tolerated with no serious adverse events reported. Sub...